Temasek Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Temasek Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-244,582	Closed	-$41.6M	–	61
2018 Q2	$41.6M	Hold	244,582	–	–	0.22%	43
2018 Q1	$39.9M	Hold	244,582	–	–	0.22%	43
2017 Q4	$36.7M	Hold	244,582	–	–	0.23%	41
2017 Q3	$37.2M	Buy	244,582 +50,383	+26%	+$7.58M	0.22%	38
2017 Q2	$25M	Buy	+194,199	New	+$23.4M	0.16%	41

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Temasek Holdings's VRTX Position: Q3 2018 in Review

Temasek Holdings sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 244,582 shares — an estimated $41.6M sold.

Temasek Holdings first reported a position in VRTX in Q2 2017 and held it in 5 quarters. The position peaked at $41.6M in Q2 2018. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Temasek Holdings reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Temasek Holdings sold 244,582 Vertex Pharmaceuticals shares in Q3 2018, an estimated $41.6M.
Temasek Holdings first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Temasek Holdings's Vertex Pharmaceuticals position peaked at $41.6M in Q2 2018.
696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Temasek Holdings's 13F filing for Q3 2018, filed 14 Nov 2018.